Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT05677971
Registration number
NCT05677971
Ethics application status
Date submitted
28/12/2022
Date registered
10/01/2023
Titles & IDs
Public title
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
Query!
Scientific title
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis
Query!
Secondary ID [1]
0
0
2022-501943-34
Query!
Secondary ID [2]
0
0
TAK-999-3001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Alpha1-Antitrypsin Deficiency
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Cancer
0
0
0
0
Query!
Liver
Query!
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Fazirsiran Injection
Other interventions - Placebo
Experimental: Fazirsiran - Participants will receive fazirsiran 200 milligram per milliliter (mg/ml) subcutaneous (SC) injection on Day 1, at Week 4, and then every 12 weeks (Q12 W) thereafter up to Week 196.
Placebo comparator: Placebo - Participants will receive placebo on Day 1, at Week 4, and Q12 W thereafter up to Week 196.
Treatment: Drugs: Fazirsiran Injection
Participants will receive fazirsiran 200 mg/ml SC injection on Day 1, at Week 4, and Q12 W thereafter up to Week 196.
Other interventions: Placebo
Participants will receive placebo (sterile normal saline \[0.9% NaCl\]) SC injection on Day 1, at Week 4, and Q12 W thereafter up to Week 196.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Reduction From Baseline of at Least 1 Stage of Histologic Fibrosis (METAVIR Staging) in the Centrally Read Liver Biopsy at Week 106 in AATD-LD With METAVIR Stage F2 and F3 Fibrosis
Query!
Assessment method [1]
0
0
Reduction from baseline of at least 1 stage of histologic fibrosis METAVIR staging in the centrally read liver biopsy at Week 106 in AATD-LD with METAVIR stage F2 and F3 fibrosis will be assessed.
Query!
Timepoint [1]
0
0
Baseline, Week 106
Query!
Secondary outcome [1]
0
0
Percent Change from Baseline in Intrahepatic Z-AAT Protein in Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (AATD-LD) with METAVIR Stage F2 to F3 Fibrosis at Week 106
Query!
Assessment method [1]
0
0
Percent change from baseline in intrahepatic Z-AAT protein in AATD-LD with METAVIR stage F2 to F3 fibrosis will be assessed.
Query!
Timepoint [1]
0
0
Baseline, Week 106
Query!
Secondary outcome [2]
0
0
Reduction From Baseline of at Least 1 Stage of Histologic Fibrosis (METAVIR Staging) in the Centrally Read Liver Biopsy
Query!
Assessment method [2]
0
0
Reduction from baseline of at least 1 stage of histologic fibrosis (METAVIR Staging) in the centrally read liver biopsy in participants with AATD-LD with METAVIR stage fibrosis will be assessed.
Query!
Timepoint [2]
0
0
Baseline, Week 106 and Week 202
Query!
Secondary outcome [3]
0
0
Number of Participants With Liver Related Clinical Events up to Week 202
Query!
Assessment method [3]
0
0
Number of participants with any qualifying liver-related clinical events up to Week 202 in AATD-LD with METAVIR stage F2 to F4 fibrosis will be assessed.
Query!
Timepoint [3]
0
0
Baseline up to Week 202
Query!
Secondary outcome [4]
0
0
Change From Baseline in Serum Z-Alpha-1 Antitrypsin (Z-AAT) Protein
Query!
Assessment method [4]
0
0
Change from baseline in serum Z-AAT protein in participants with AATD-LD with METAVIR stage fibrosis will be assessed.
Query!
Timepoint [4]
0
0
Baseline, Week 106, Week 202
Query!
Secondary outcome [5]
0
0
Change From Baseline in Intrahepatic Z-AAT Protein Polymer Burden Assessed by Periodic Acid Schiff Plus Diastase (PAS+D) Staining
Query!
Assessment method [5]
0
0
Change from baseline in intrahepatic Z-AAT protein polymer burden assessed by PAS+D staining liver biopsy in participants with AATD-LD with METAVIR stage fibrosis will be assessed.
Query!
Timepoint [5]
0
0
Baseline, Week 106, Week 202
Query!
Secondary outcome [6]
0
0
Change From Baseline in Intrahepatic Portal Inflammation
Query!
Assessment method [6]
0
0
Change from baseline in intrahepatic portal inflammation liver biopsy in participants with AATD-LD with METAVIR stage fibrosis will be assessed.
Query!
Timepoint [6]
0
0
Baseline, Week 106, Week 202
Query!
Secondary outcome [7]
0
0
Change From Baseline in Vibration-Controlled Transient Elastography (VCTE)/Magnetic Resonance Elastography (MRE)-derived Liver Stiffness
Query!
Assessment method [7]
0
0
Change from baseline in VCTE/MRE-derived liver stiffness in participants with AATD-LD with METAVIR stage fibrosis will be assessed.
Query!
Timepoint [7]
0
0
Baseline, Week 106, Week 196 and Week 202
Query!
Secondary outcome [8]
0
0
Change From Baseline in Model of End-Stage Liver Disease (MELD) Score
Query!
Assessment method [8]
0
0
The MELD scoring system is used to assess the severity of chronic liver disease. The MELD score is derived from the participant's serum total bilirubin, serum creatinine, and prothrombin international normalized ratio (INR): 3.78\*log e serum bilirubin (milligram per deciliter \[mg/dL\]) + 11.20\* log e INR + 9.57\* log e serum creatinine (mg/dL) + 6.43 (constant for liver disease etiology). The MELD score ranges from 6 to 40 with higher scores indicating more severe liver disease and a worse outcome. Change from baseline in MELD score in participants with AATD-LD with METAVIR stage fibrosis will be assessed.
Query!
Timepoint [8]
0
0
Baseline, Week 106, and Week 202
Query!
Secondary outcome [9]
0
0
Change From Baseline in Liver Injury
Query!
Assessment method [9]
0
0
Change from baseline in liver injury in participants with AATD-LD with METAVIR stage fibrosis will be assessed.
Query!
Timepoint [9]
0
0
Baseline, Week 106 and Week 202
Query!
Secondary outcome [10]
0
0
Percent Change from Baseline in Intrahepatic Z-AAT Protein in AATD-LD With METAVIR Stage F2 to F4 Fibrosis
Query!
Assessment method [10]
0
0
Percent change from baseline in intrahepatic Z-AAT protein in AATD-LD with METAVIR stage F2 to F4 fibrosis will be assessed.
Query!
Timepoint [10]
0
0
Baseline, Week 106 and Week 202
Query!
Secondary outcome [11]
0
0
Observed Plasma Concentrations of Fazirsiran
Query!
Assessment method [11]
0
0
Observed Plasma Concentrations of Fazirsiran will be assessed.
Query!
Timepoint [11]
0
0
Pre-dose up to Week 196
Query!
Secondary outcome [12]
0
0
Number of Participants with Treatment-emergent adverse event (TEAE) and Serious TEAEs
Query!
Assessment method [12]
0
0
An AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this investigational product (IP) or medicinal product. An SAE is any untoward medical occurrence that at any dose met one, more of the following criteria: results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event. A TEAE is any event emerging or manifesting at or after the initiation of treatment with an IP or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the IP or medicinal product. Number of participants with TEAEs and serious TEAEs will be assessed.
Query!
Timepoint [12]
0
0
From start of study drug administration up to end of the study (EOS) (Week 220)
Query!
Secondary outcome [13]
0
0
Number of Participants with Clinically Significant Declines in Lung Function Parameters
Query!
Assessment method [13]
0
0
Standard pulmonary function parameters measured will be used to study lung function.
Query!
Timepoint [13]
0
0
From start of study drug administration up to EOS (Week 220)
Query!
Secondary outcome [14]
0
0
Change From Baseline in Whole Lung PD15 (15th percentile point) Measured by CT lung Densitometry
Query!
Assessment method [14]
0
0
Change from baseline in whole lung PD15 (15th percentile point) as measured by CT lung densitometry will be assessed.
Query!
Timepoint [14]
0
0
Baseline up to EOS (Week 220)
Query!
Secondary outcome [15]
0
0
Number of Participants with Clinically Significant Change in Vital Signs
Query!
Assessment method [15]
0
0
Vital signs will include body temperature, respiratory rate, blood pressure, pulse and amount of oxygen in the blood. Any change in vital signs which are deemed clinically significant by the investigator will be reported as AE.
Query!
Timepoint [15]
0
0
From start of study drug administration up to EOS (Week 220)
Query!
Secondary outcome [16]
0
0
Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Parameters
Query!
Assessment method [16]
0
0
12-lead ECG will be evaluated. Any change in ECG assessments which are deemed clinically significant by the investigator will be reported as AE.
Query!
Timepoint [16]
0
0
From start of study drug administration up to EOS (Week 220)
Query!
Secondary outcome [17]
0
0
Number of Participants with Clinically Significant Changes in Clinical Laboratory Assessments
Query!
Assessment method [17]
0
0
Clinical laboratory assessments include hematology, serum chemistry, coagulation, and urinalysis. Changes in laboratory values may be considered as AE if they were judged to be clinically significant.
Query!
Timepoint [17]
0
0
From start of study drug administration up to EOS (Week 220)
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
* The participant must have a diagnosis of the Z allele homozygotes (PiZZ) genotype AATD. PiZZ diagnosis from source verifiable medical records is permitted. Otherwise, participants must undergo PiZZ confirmatory testing (genotyping for PiS and PiZ alleles) at screening. PiMZ or PiSZ genotypes are not permitted.
* The participant, of any sex, is aged 18 to 75 years, inclusive.
* The participant's liver biopsy core sample collected should meet the requirements of the protocol.
* The participant has evidence of METAVIR stage F2, F3, or F4 liver fibrosis, evaluated by a centrally read baseline liver biopsy during the screening period; or confirmed as meeting all the entry criteria by central reading of a previous biopsy conducted within 6 months before the estimated enrollment date using an adequate liver biopsy and slides as defined in the study laboratory manual.
* The participant has a pulmonary status meeting the protocol's requirements.
* It must be confirmed that the participant does not have HCC. Participants will be screened for HCC with alpha-fetoprotein (AFP) and abdominal ultrasound. If the participant has any of the following, they will be required to have contrast-enhanced CT or MRI imaging to exclude HCC before randomization.
* An adult participant must have a body mass index (BMI) between 18.0 and 39.0 kilograms per meter square (kg^m2), inclusive.
* The participant is a nonsmoker for at least 12 months before screening.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion Criteria
* The participant has a history of liver decompensating events (overt hepatic encephalopathy [West Haven Grade >=2] documented by a physician, clinically significant ascites, spontaneous bacterial peritonitis, GI bleeding from varices, hepatopulmonary syndrome, hepatorenal syndrome, portal pulmonary hypertension, or portal gastropathy).
* The participant has a history of the presence of medium or large varices or varices with red wale signs based on a previous esophagogastroduodenoscopy (EGD) within 6 months before the estimated enrollment date. For certain participants, an EGD will be required at screening if there is no EGD available within 6 months before the estimated enrollment date. Presence of small varices with no red wale signs on EGD and no history of bleeding will be acceptable for study eligibility.
* The participant has evidence of other forms of chronic liver diseases, including viral hepatitis B or C, primary biliary cirrhosis, primary sclerosing cholangitis, Wilson disease, alcoholic hepatitis, hemochromatosis, liver cancer, history of biliary diversion, or autoimmune hepatitis.
* The participant has alanine transaminase (ALT) or aspartate transaminase (AST) levels >250 units per liter (U/L).
* The participant has a platelet count <60,000 per cubic millimeter (mm^3) (<60 × 10^9 per liter [10^9/L]).
* The participant has albumin <=2.8 gram per deciliter (g/dL) (28 grams per deciliter [g/L]).
* The participant has international normalized ratio (INR) >=1.7.
* The participant is expected to have severe and unavoidable high-level exposure to inhaled pulmonary toxins during the study such as may occur with occupational exposure to mineral dusts or metals.
* The participant has a history of drug abuse (such as cocaine, phencyclidine) within 1 year before the screening visit or has a positive urine drug screen at screening.
* The participant has previously been treated with fazirsiran or any other RNAi for AATD-LD.
* The participant has portal vein thrombosis.
* The participant has a prior transjugular portosystemic shunt procedure.
* The participant has a history of malignancy within the last 5 years, except for adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical cancer. Participants with other curatively treated malignancies who have no evidence of metastatic disease and a greater than 1-year disease-free interval may be entered after approval by the medical monitor.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
6/03/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
31/03/2029
Query!
Actual
Query!
Sample size
Target
160
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
SA,VIC
Query!
Recruitment hospital [1]
0
0
Royal Adelaide Hospital - Adelaide
Query!
Recruitment hospital [2]
0
0
St Vincents Hospital Melbourne - PPDS - Fitzroy
Query!
Recruitment postcode(s) [1]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
3065 - Fitzroy
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Indiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Iowa
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Massachusetts
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Michigan
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Missouri
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New York
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Ohio
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Pennsylvania
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
South Carolina
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Tennessee
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Texas
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Virginia
Query!
Country [18]
0
0
Austria
Query!
State/province [18]
0
0
Graz
Query!
Country [19]
0
0
Austria
Query!
State/province [19]
0
0
Klagenfurt
Query!
Country [20]
0
0
Austria
Query!
State/province [20]
0
0
Vienna
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Antwerpen
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Leuven
Query!
Country [23]
0
0
Brazil
Query!
State/province [23]
0
0
São Paulo
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Ontario
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Clichy
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Lyon
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Rennes
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Toulouse
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Val-de-Marne
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Aachen
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Berlin
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Hannover
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Tübingen
Query!
Country [34]
0
0
Italy
Query!
State/province [34]
0
0
Pavia
Query!
Country [35]
0
0
Poland
Query!
State/province [35]
0
0
Slaskie
Query!
Country [36]
0
0
Portugal
Query!
State/province [36]
0
0
Braga
Query!
Country [37]
0
0
Portugal
Query!
State/province [37]
0
0
Funchal
Query!
Country [38]
0
0
Portugal
Query!
State/province [38]
0
0
Porto
Query!
Country [39]
0
0
Spain
Query!
State/province [39]
0
0
Barcelona
Query!
Country [40]
0
0
Switzerland
Query!
State/province [40]
0
0
Bern
Query!
Country [41]
0
0
United Kingdom
Query!
State/province [41]
0
0
Edinburgh
Query!
Country [42]
0
0
United Kingdom
Query!
State/province [42]
0
0
London
Query!
Country [43]
0
0
United Kingdom
Query!
State/province [43]
0
0
Nottingham
Query!
Country [44]
0
0
United Kingdom
Query!
State/province [44]
0
0
Plymouth
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Takeda
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Takeda Development Center Americas, Inc.
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down the disease worsening in the liver, to get information on how fazirsiran affects the body (called pharmacodynamics), to learn if fazirsiran reduces other liver injury (inflammation) and the abnormal Z-AAT protein in the liver, to get information on how the body processes fazirsiran (called pharmacokinetics), to test how well fazirsiran works compared with a placebo in improving measures of liver scarring including imaging and liver biomarkers (substances in the blood that the body normally makes and help show if liver function is improving, staying the same, or getting worse) as well as to check for side effects in participants treated with fazirsiran compared with those who received placebo. Participants will either receive fazirsiran or placebo. Liver biopsies, a way of collecting a small tissue sample from the liver, will be taken twice during this study.
Query!
Trial website
https://clinicaltrials.gov/study/NCT05677971
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Study Director
Query!
Address
0
0
Takeda
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Takeda Contact
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1-877-825-3327
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Informed consent form (ICF), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
Query!
Available to whom?
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://vivli.org/ourmember/takeda/
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT05677971